vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and WRAP TECHNOLOGIES, INC. (WRAP). Click either name above to swap in a different company.

WRAP TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($1.4M vs $1.4M, roughly 1.0× FATE THERAPEUTICS INC). On growth, WRAP TECHNOLOGIES, INC. posted the faster year-over-year revenue change (62.3% vs -26.4%). WRAP TECHNOLOGIES, INC. produced more free cash flow last quarter ($-2.7M vs $-112.0M). Over the past eight quarters, WRAP TECHNOLOGIES, INC.'s revenue compounded faster (-2.5% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Wrap Technologies, Inc. develops non-lethal safety solutions for law enforcement, corrections, and private security sectors across North America and global markets. Its core products include remote restraint devices and training services designed to reduce use-of-force injuries and improve public safety outcomes.

FATE vs WRAP — Head-to-Head

Bigger by revenue
WRAP
WRAP
1.0× larger
WRAP
$1.4M
$1.4M
FATE
Growing faster (revenue YoY)
WRAP
WRAP
+88.7% gap
WRAP
62.3%
-26.4%
FATE
More free cash flow
WRAP
WRAP
$109.4M more FCF
WRAP
$-2.7M
$-112.0M
FATE
Faster 2-yr revenue CAGR
WRAP
WRAP
Annualised
WRAP
-2.5%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
WRAP
WRAP
Revenue
$1.4M
$1.4M
Net Profit
$-3.9M
Gross Margin
52.3%
Operating Margin
-281.1%
Net Margin
-280.9%
Revenue YoY
-26.4%
62.3%
Net Profit YoY
37.9%
48.1%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
WRAP
WRAP
Q4 25
$1.4M
$1.4M
Q3 25
$1.7M
$1.5M
Q2 25
$1.9M
$1.0M
Q1 25
$1.6M
$765.0K
Q4 24
$1.9M
$865.0K
Q3 24
$3.1M
$593.0K
Q2 24
$6.8M
$1.6M
Q1 24
$1.9M
$1.5M
Net Profit
FATE
FATE
WRAP
WRAP
Q4 25
$-3.9M
Q3 25
$-32.3M
$-2.8M
Q2 25
$-34.1M
$-3.7M
Q1 25
$-37.6M
$109.0K
Q4 24
$-7.6M
Q3 24
$-47.7M
$2.0M
Q2 24
$-38.4M
$-385.0K
Q1 24
$-48.0M
$117.0K
Gross Margin
FATE
FATE
WRAP
WRAP
Q4 25
52.3%
Q3 25
59.2%
Q2 25
48.1%
Q1 25
77.8%
Q4 24
47.4%
Q3 24
39.6%
Q2 24
62.6%
Q1 24
56.6%
Operating Margin
FATE
FATE
WRAP
WRAP
Q4 25
-281.1%
Q3 25
-1995.1%
-185.2%
Q2 25
-1938.5%
-282.2%
Q1 25
-2534.1%
-512.7%
Q4 24
-535.5%
Q3 24
-1703.9%
-611.5%
Q2 24
-665.7%
-201.5%
Q1 24
-2652.9%
-280.4%
Net Margin
FATE
FATE
WRAP
WRAP
Q4 25
-280.9%
Q3 25
-1852.4%
-186.0%
Q2 25
-1786.6%
-368.3%
Q1 25
-2309.5%
14.2%
Q4 24
-878.3%
Q3 24
-1551.0%
335.6%
Q2 24
-567.4%
-24.5%
Q1 24
-2493.7%
7.9%
EPS (diluted)
FATE
FATE
WRAP
WRAP
Q4 25
Q3 25
$-0.27
$-0.06
Q2 25
$-0.29
$-0.07
Q1 25
$-0.32
Q4 24
Q3 24
$-0.40
$0.04
Q2 24
$-0.33
$-0.02
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
WRAP
WRAP
Cash + ST InvestmentsLiquidity on hand
$203.7M
$3.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$11.5M
Total Assets
$318.9M
$15.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
WRAP
WRAP
Q4 25
$203.7M
$3.5M
Q3 25
$215.4M
$6.0M
Q2 25
$222.8M
$4.2M
Q1 25
$240.4M
$6.2M
Q4 24
$279.1M
$3.6M
Q3 24
$296.9M
$4.9M
Q2 24
$304.9M
$4.6M
Q1 24
$121.3M
$8.2M
Stockholders' Equity
FATE
FATE
WRAP
WRAP
Q4 25
$207.2M
$11.5M
Q3 25
$234.1M
$14.1M
Q2 25
$261.4M
$11.8M
Q1 25
$288.4M
$2.6M
Q4 24
$318.7M
$250.0K
Q3 24
$362.3M
$6.4M
Q2 24
$397.0M
$3.8M
Q1 24
$426.1M
$4.5M
Total Assets
FATE
FATE
WRAP
WRAP
Q4 25
$318.9M
$15.4M
Q3 25
$343.7M
$18.2M
Q2 25
$371.6M
$15.6M
Q1 25
$398.7M
$18.0M
Q4 24
$440.7M
$15.1M
Q3 24
$495.0M
$18.8M
Q2 24
$528.8M
$21.8M
Q1 24
$569.9M
$24.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
WRAP
WRAP
Operating Cash FlowLast quarter
$-106.1M
$-2.7M
Free Cash FlowOCF − Capex
$-112.0M
$-2.7M
FCF MarginFCF / Revenue
-8183.9%
-190.3%
Capex IntensityCapex / Revenue
434.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M
$-10.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
WRAP
WRAP
Q4 25
$-106.1M
$-2.7M
Q3 25
$-24.4M
$-2.6M
Q2 25
$-24.6M
$-1.9M
Q1 25
$-33.8M
$-3.1M
Q4 24
$-122.9M
$-1.2M
Q3 24
$-29.4M
$330.0K
Q2 24
$-32.3M
$-3.5M
Q1 24
$-33.4M
$-3.7M
Free Cash Flow
FATE
FATE
WRAP
WRAP
Q4 25
$-112.0M
$-2.7M
Q3 25
$-26.6M
$-2.7M
Q2 25
$-25.9M
$-1.9M
Q1 25
$-35.0M
$-3.1M
Q4 24
$-123.6M
$-1.2M
Q3 24
$-29.9M
Q2 24
$-32.4M
$-3.5M
Q1 24
$-33.4M
$-3.7M
FCF Margin
FATE
FATE
WRAP
WRAP
Q4 25
-8183.9%
-190.3%
Q3 25
-1526.5%
-181.1%
Q2 25
-1360.7%
-192.3%
Q1 25
-2148.9%
-401.4%
Q4 24
-6645.4%
-139.5%
Q3 24
-973.1%
Q2 24
-477.8%
-224.2%
Q1 24
-1736.9%
-253.3%
Capex Intensity
FATE
FATE
WRAP
WRAP
Q4 25
434.8%
0.5%
Q3 25
126.5%
5.7%
Q2 25
71.4%
0.6%
Q1 25
73.4%
0.3%
Q4 24
39.2%
0.1%
Q3 24
16.1%
0.0%
Q2 24
0.8%
0.1%
Q1 24
4.5%
0.9%
Cash Conversion
FATE
FATE
WRAP
WRAP
Q4 25
Q3 25
Q2 25
Q1 25
-28.16×
Q4 24
Q3 24
0.17×
Q2 24
Q1 24
-31.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons